

肝への取り込みの低下を伴うと考えられる。HMG-CoA還元酵素阻害薬は肝に取り込まれることでコレステロール低下作用を示すことから、本変異保有患者では期待する効果が得られにくいと予想される。この仮説を検証する研究が徐々に報告されつつある。

#### おわりに

本稿では一部のトランスポーター遺伝子多型のヒトでの機能評価を紹介したが、OCTsなどの他のトランスポーターでの評価も散見されている。薬物の体内動態や臨床効果の個人差に關与することを裏づけるデータが得られつつある。薬物代謝酵素やトランスポーター遺伝子多型により、大まかな個人の特徴づけが可能となってきた。さらなる精度を高めた実用化が望まれる。

#### 文 献

- 1) Ieiri I, et al: The MDR1 (ABCB1) gene polymorphism and its clinical implications. *Clin Pharmacokinet* 43 (9): 553-576, 2004.
- 2) Takane H, et al: Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. *J Pharmacol Exp Ther* 311 (3): 1179-1187, 2004.
- 3) Kurata Y, et al: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. *Clin Pharmacol Ther* 72 (2): 209-219, 2002.
- 4) Kobayashi D, et al: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. *Drug Metab Dispos* 33 (1): 94-101, 2005.
- 5) Sparreboom A, et al: Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. *Clin Pharmacol Ther* 76 (1): 38-44, 2004.
- 6) Ieiri I, et al: Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. *Hepato Res* 30 (2): 91-95, 2004.
- 7) Nishizato Y, et al: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. *Clin Pharmacol Ther* 73 (6): 554-565, 2003.

---

### Pharmacogenomics of Drug Transporters and Its Pharmacokinetic/Clinical Implications

Ichiro Ieiri

Department of Hospital Pharmacy, Tottori University Hospital

# CHAPTER

## Single nucleotide polymorphism typing using degenerate-oligonucleotide-primed PCR-amplified products

Makoto Bannai<sup>1</sup> and Katsushi Tokunaga<sup>2</sup>

<sup>1</sup>Biomedical Business R&D Department, Olympus Corporation, 2-3 Kuboyama-cho, Hachioji-shi, Tokyo 192-8512, Japan; <sup>2</sup>Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

---

### 1. INTRODUCTION

WGA is a valuable technique for amplifying a limited amount of DNA in a sequence-independent fashion. WGA methods have been adopted for minimization of the amount of genomic DNA needed for a number of biological assays including large-scale typing of single nucleotide polymorphisms (SNPs), microsatellite genotyping, and comparative genomic hybridization (CGH).

WGA by degenerate-oligonucleotide-primed PCR (DOP-PCR) was first described by Telenius *et al.* (1) and allows complete genome coverage in a single reaction. In contrast to the pairs of target-specific primer sequences used in traditional PCR, only a single primer, which has defined sequences at its 5' (containing a *Xho*I restriction site, highlighted in bold) and 3' ends and a random hexamer sequence between them (5'-CCGACTCGAGNNNNNNATGTGG-3'), is used for DOP-PCR. Compared with completely degenerate primers, such as those used for primer-extension pre-amplification PCR (PEP-PCR) (5'-NNNNNNNNNNNNNNN-3'), the primer for DOP-PCR is relatively specific (2).

DOP-PCR is comprised of two different cycling stages, low stringency and high stringency. At low stringency, the 3' end of the primer binds at sites in the genome complementary to the 6 bp well-defined sequence (approximately 10<sup>6</sup> sites in the human genome). The adjacent random hexamer sequence, which displays all possible combinations of the nucleotides A, G, C, and T, then enables efficient primer annealing and the start of the DOP-PCR-based WGA reaction.

Since its conception, several modifications of the basic DOP-PCR protocol have been devised with the purpose of lowering the required amount of starting template (3) and increasing yield (4), fidelity, and fragment length (5), in order to provide better coverage of the genome. However, all have used the same basic methodology.

## 2. METHODS AND APPROACHES

### 2.1. Methodology of DOP-PCR

---

Within a single PCR tube, low-temperature annealing and extension in the first five to eight cycles of DOP-PCR occurs at many binding sites in the genome (see *Fig. 1a* and *Protocol 2, Stage 1* – low stringency) and tags these sequences with the DOP primer. Thereafter, the annealing temperature of the PCR (>25 cycles) is increased to allow more specific priming and amplification of the tagged sequence (see *Fig. 1a* and *Protocol 2, Stage 2* – high stringency). DOP-PCR amplification ideally results in a smear of DNA fragments (200–1000 bp) that are visible on an agarose gel stained with ethidium bromide (see *Fig. 1b*).



### 2.2. Applications of DOP-PCR

---

DOP-PCR is often used as the first step in *in situ* hybridization for flow-sorted (1, 6) or microdissected (7) chromosomes and for CGH (7, 8). This approach has been successfully modified and applied to genomic DNA for genotyping of microsatellites (9) and for typing of SNPs (10–12). In this chapter, we describe sequence-specific primer PCR (SSP-PCR) followed by fluorescence correlation spectroscopy (FCS) as a method for applying DOP-PCR to SNP typing (11).

## 3. RECOMMENDED PROTOCOLS

Although we have named specific suppliers for the reagents and equipment used in this chapter, other manufacturers' products are likely to generate similar results. However, it is up to the user to test this.



**Figure 1. DOP-PCR.**

(a) Graphical representation of the steps involved in DOP-PCR. Low-temperature annealing and extension in the first five to eight cycles of DOP-PCR occurs at many binding sites in the genome (Stage 1) and tags these sequences with the DOP primer. Thereafter, the annealing temperature of the PCR (>25 cycles) is increased to allow more specific priming and amplification of the tagged sequence (Stage 2). (b) Agarose gel stained with ethidium bromide displaying the smear of DNA fragments typically obtained from DOP-PCR WGA. (Lane 1) 100 bp ladder; (lane 2) DOP-PCR product obtained from DNA extracted from formalin-fixed, paraffin-embedded tissue; (lane 3) DOP-PCR product obtained from DNA extracted from fresh tissue; (lane 4) negative control.

## Protocol 1

### Genomic DNA extraction and quantification

#### Equipment and Reagents

- QIAamp DNA Blood Midi Kit (Qiagen)
- PicoGreen dsDNA quantitation reagent (Molecular Probes)
- 10 mM Tris-HCl (pH 8.0) containing 0.1 mM EDTA
- Fluorescence-based microplate reader

#### Method

1. Isolate genomic DNA from peripheral blood using the QIAamp DNA Blood Midi Kit according to the manufacturer's instructions.
2. Measure the genomic DNA concentration using the PicoGreen dsDNA quantitation reagent according to the manufacturer's instructions.
3. Dilute the DNA samples to 10 ng/ $\mu$ l with 10 mM Tris-HCl (pH 8.0) containing 0.1 mM EDTA.

DNA yields of approximately 4–6  $\mu$ g are typically obtained in a 100  $\mu$ l reaction. The diluted DOP-PCR product (approximately 10–15 ng/ $\mu$ l) can be used as template in a subsequent PCR to generate fragments including SNP sites. The PCR products can then be sequenced.

SSP-PCR followed by FCS is applied for high-throughput SNP typing and has been described previously (11). The first PCR is followed by SSP-PCR using the product from the first PCR as template. Allele-specific, semi-nested primers are used for the SSP-PCR. They differ in a single nucleotide at the 3' end and are coupled to different fluorescence dyes – 6-carboxytetramethylrhodamine (TAMRA) or cyanine 5 (Cy5). Because the movement of DNA fragments in a solution depends on their size, primers (smaller molecules) move faster than SSP-PCR-amplified fragments (larger molecules) in the PCR product solution. When the narrow laser beam spots DNA fragments in the solution (in a 1 fl volume), the signals from the fluorescent-labeled molecules are detected by a highly sensitive spectrophotometer, allowing determination of the numbers and sizes of both primers and amplified fragments. The percentage of allele-specific amplified fragments relative to the total number of fluorescent-labeled molecules can then be determined using the single-molecule fluorescence detection system.

## Protocol 2

### DOP-PCR<sup>a</sup>

#### Equipment and Reagents

- 4  $\mu$ M DOP primer (5'-CCGACTCGAGNNNNNNATGTGG-3') (Sigma Genosys)
- TaKaRa LA *Taq* polymerase (5 units/ $\mu$ l) and accompanying 2 $\times$  GC buffer (Takara Bio)
- 400  $\mu$ M dNTP mix (Takara Bio)
- Nuclease-free water (Sigma)
- 10 mM Tris-HCl (pH 8.0) containing 0.1 mM EDTA
- Thermal cycler (MJ Research)
- Agarose (Amersham Biosciences)
- Ethidium bromide (10 mg/ml) (Sigma)
- 1 $\times$  TBE buffer (89 mM Tris; 89 mM boric acid; 2 mM EDTA)
- Electrophoresis apparatus
- Spectrophotometer

#### Method

1. Use 10 ng of genomic DNA as a template in a DOP-PCR mixture containing 1  $\mu$ l of TaKaRa LA *Taq* polymerase, 50  $\mu$ l of 2 $\times$  GC buffer, 400  $\mu$ M dNTPs, 4  $\mu$ M DOP primer and nuclease-free water up to a final volume of 100  $\mu$ l<sup>b</sup>.
2. Perform DOP-PCR in a thermal cycler with an initial incubation of 93°C for 1 min<sup>c</sup>, followed by eight cycles of 93°C for 1 min, 30°C for 1 min, and 72°C for 3 min (Stage 1)<sup>d</sup>, and 28 cycles of 93°C for 1 min, 60°C for 1 min, and 72°C for 3 min (Stage 2)<sup>e</sup>.
3. Run 5–10  $\mu$ l of the DOP-PCR products including the negative control on a 1% agarose gel to assess fragment size and the success of the reaction<sup>f</sup>.
4. Dilute the DOP-PCR products with four volumes of 10 mM Tris-HCl (pH 8.0) containing 0.1 mM EDTA and store at -20°C until use.

#### Notes

<sup>a</sup>The DOP-PCR method is as described previously (9) with slight modifications.

<sup>b</sup>It is important to include a negative control, which includes all of the reaction constituents with the exception of DNA.

<sup>c</sup>The initial denaturation for 8 min at 96°C, as suggested in (9), can be omitted with no effect on the efficiency of the DOP-PCR protocol, at least for the PCR targets tested in our work (11).

<sup>d</sup>Low-temperature annealing and extension, which occurs at several binding sites across the genome.

<sup>e</sup>Elevated annealing temperature, allowing more specific priming of the fragments tagged with the primer sequence.

<sup>f</sup>The negative control lane should not show any amplification. If it does, this suggests possible contamination and therefore reactions must be repeated. We would suggest using fresh reagents.

## Protocol 3

### Direct sequencing for SNP analysis

#### Equipment and Reagents

- AmpliTaq Gold DNA polymerase (5 units/ $\mu$ l) with the GeneAmp 10 $\times$  PCR Gold Buffer (Applied Biosystems), or another comparable hot-start enzyme
- 500 nM PCR primers (Sigma Genosys)
- 25 mM MgCl<sub>2</sub> stock solution (Roche Diagnostics)
- 200  $\mu$ M dNTP mix (Takara Bio)
- QIAquick PCR Purification Kit (Qiagen)
- Spectrophotometer
- BigDye Terminator Version 3.1 Cycle Sequencing Kit (Applied Biosystems)
- DNA sequencer (Applied Biosystems)
- Thermal cycler (MJ Research)
- SEQSCAPE Version 2.0 (Applied Biosystems)

#### Method

1. Prepare a 10  $\mu$ l PCR mixture containing 1  $\mu$ l of the diluted DOP-PCR product (approximately 10–15 ng of amplified DNA), 0.5 units of AmpliTaq Gold DNA polymerase, 200  $\mu$ M dNTPs, 3.1 mM MgCl<sub>2</sub>, and 500 nM of each primer.
2. PCR amplify using the following protocol: initial incubation at 95°C for 10 min; followed by 40 cycles of 95°C for 30 s, optimal annealing temperature for each primer pair<sup>a</sup> for 30 s, and 72°C for 1 min; and a final incubation at 72°C for 10 min.
3. Purify the PCR products using the QIAquick PCR Purification Kit, following the manufacturer's instructions.
4. Determine the yield of the PCR by measuring absorbance at 260 nm using a spectrophotometer.
5. Using the PCR products as templates, perform a cycle sequencing reaction using the BigDye Terminator Version 3.1 Kit according to the manufacturer's instructions<sup>b</sup>.
6. Perform direct sequencing using a DNA sequencer and analyze the SNP types using SEQSCAPE Version 2.0 software<sup>c</sup>.

#### Notes

<sup>a</sup>The primer pairs and optimal annealing temperatures used for these experiments are specific for the SNPs of interest and thus should be determined for each experiment.

<sup>b</sup>The quantity of PCR product used for sequencing varies depending on the size of the product. For 100–200 bp, use 1–3 ng of DNA; for 200–500 bp, use 3–10 ng of DNA; for 500–1000 bp, use 5–20 ng of DNA; for 1000–2000 bp, use 10–40 ng of DNA; for >2000 bp, use 20–50 ng of DNA ([www.appliedbiosystems.com](http://www.appliedbiosystems.com)).

<sup>c</sup>Other instruments and software may also be used for the sequence analysis.

## Protocol 4

### High-throughput SNP typing<sup>a</sup>

#### Equipment and Reagents

- AmpliTaq DNA polymerase, Stoffel fragment (5 units/ $\mu$ l) with the 10 $\times$  Stoffel buffer (Applied Biosystems)
- 20 nM TAMRA-labeled SSP-PCR primer (Sigma Genosys)
- 20 nM Cy5-labeled SSP-PCR primer (Sigma Genosys)
- 25 mM MgCl<sub>2</sub> stock solution (Roche Diagnostics)
- 200  $\mu$ M dNTP mix (Takara Bio)
- 10 mM Tris-HCl (pH 8.0)
- 384-Well, hard-shell, thin-walled plates (MJ Research)
- 384-Well, glass-bottomed plates (Olympus Corporation)
- Single-molecule fluorescence detection (SMFD) system (Olympus Corporation)
- Thermal cycler (MJ Research)

#### Method


1. Using diluted DOP-PCR products as templates, perform PCR to amplify a fragment including an SNP site (see *Protocol 3*).
2. Perform SSP-PCR using the two competitive allele-specific primers in a 10  $\mu$ l reaction containing 1 $\times$  Stoffel buffer, 0.5 units of AmpliTaq DNA polymerase Stoffel fragment, 200  $\mu$ M dNTPs, 2.5 mM MgCl<sub>2</sub>, 20 nM of each primer, and 0.5  $\mu$ l of the first PCR product as template.
3. PCR amplify in 384-well, hard-shell, thin-walled plates using the following protocol: initial incubation at 95°C for 2 min; followed by 40 cycles of ramping at 0.1°C/s to 95°C, 95°C for 30 s, optimal annealing temperature for each SNP for 30 s, and 72°C for 30 s; and a final incubation at 72°C for 10 min.
4. Transfer 4  $\mu$ l of the SSP-PCR products into separate wells of a 384-well, glass-bottomed plate and dilute with 24  $\mu$ l of 10 mM Tris-HCl (pH 8.0).
5. Analyze SNPs in the SSP-PCR products by FCS using the SMFD system<sup>b</sup>. Measure fluorescence at both 543 and 633 nm excitation wavelengths. Subject the mixture to FCS measurements and perform three 3 s measurements for each well.
6. Analyze the SNP genotypes using the software supplied with the SMFD system (examples of typing results are shown in *Fig. 2*).

#### Notes

<sup>a</sup>We perform both the first PCR and SSP-PCR in a thermal cycler capable of holding 384-well plates, as this enables us to perform high-throughput SNP analysis. Thermal cyclers capable of holding individual 0.2 or 0.5 ml tubes or 96-well plates are likely to be suitable.

<sup>b</sup>Other instruments and software may also be used for sequence analysis.





**Figure 2. SNP typing results as determined by FCS using DOP-PCR products as templates.**

A total of 216 samples was analyzed. The genomic DNA concentration was measured precisely using the PicoGreen method, and 10 ng of genomic DNA was used as the template for a 100  $\mu$ l DOP-PCR. One microlitre of fivefold-diluted product was used as the template for a subsequent PCR. Genotypes were determined by sequencing of the genomic DNAs. (a) TNFR1 IVS4-35 C>T:  $\diamond$ , TT;  $\square$ , TC;  $\triangle$ , CC. (b) TNFR1 IVS6+8 G>A:  $\diamond$ , GG;  $\square$ , GA;  $\triangle$ , AA. (c) TNFR2 K56K:  $\diamond$ , GG;  $\square$ , GA;  $\triangle$ , AA. (d) TNFR2 M196R:  $\diamond$ , GG;  $\square$ , GT;  $\triangle$ , TT. The x-axis shows the percentage of amplified product for 633 nm (Cy5), while the y-axis shows the percentage of amplified product for 543 nm (TAMRA).

### 3.1. Results

#### 3.1.1. Genome coverage


Cheung & Nelson (9) showed by microsatellite genotyping that a large proportion of the genome can be amplified by DOP-PCR. In their study, all 55 microsatellites tested were efficiently amplified from the DOP-PCR products. Our experience of SNP analysis also indicates that most regions in the genome can be amplified by DOP-PCR. We have succeeded in PCR amplification of 431 out of 441 SNPs (98%) using DOP-PCR products as PCR templates. Telenius *et al.* (1) demonstrated that a single degenerate primer can efficiently amplify DNA from the genomes of non-human species, including mouse and *Drosophila*.

### 3.1.2. Starting template DNA

Precise measurement and normalization of the amount of template DNA is important. DOP-PCR is performed in a 100  $\mu$ l reaction mixture using 10 ng of genomic DNA as starting template. A shortage of genomic DNA template sometimes leads to a lower reliability of genotyping for some SNPs. Thus, the PicoGreen method is used for precise measurement of the genomic DNA concentration. The concentration of genomic DNA is adjusted with 10 mM Tris-HCl (pH 8.0) containing 0.1 mM EDTA.

### 3.1.3. DOP-PCR yield

DOP-PCR can amplify genomic DNA more than 100-fold. Using 10 ng of genomic DNA as a template for DOP-PCR, 500 different PCRs are possible from the resulting WGA product (see *Figs. 2 and 3*). SNP typing sometimes failed when we used lower amounts of DOP-PCR products, indicating that further dilution of DOP-PCR products results in reduced reliability of genotyping for some SNPs. Cheung & Nelson (9) showed that 40 ng of genomic DNA was amplified with DOP-PCR to an average of 8  $\mu$ g (200-fold amplification) as determined by  $A_{260}$ . In the same study, all microsatellite markers tested were amplified 200–600-fold from 0.6–40 ng of genomic DNA.



**Figure 3. SNP typing results using DOP-PCR and MDA products as templates as determined by FCS (using precisely determined concentrations of genomic DNA).**


SNP TNFR1 IVS4-35 C>T was analyzed in 216 samples. The genomic DNA concentration was measured precisely by the PicoGreen method. (a) Ten nanograms of genomic DNA was used as the template for a 100  $\mu$ l DOP-PCR. One microlitre of fivefold-diluted product was used as the template for a subsequent PCR. (b) Ten nanograms of genomic DNA was used as the template for a 20  $\mu$ l MDA reaction (using the GenomiPhi Kit, Amersham Biosciences, according to the manufacturer's instructions). One microlitre of 25-fold-diluted product was used as the template for a subsequent PCR. Genotypes were determined by sequencing of genomic DNAs. Samples are denoted by the corresponding genotype symbols as follows:  $\diamond$ , TT;  $\square$ , TC;  $\triangle$ , CC. The x-axis shows the percentage of amplified product for 633 nm (Cy5), while the y-axis shows the percentage of amplified product for 543 nm (TAMRA).

### 3.1.4. DOP-PCR product size

The DOP-PCR products range from 200 to 1000 bp based on ethidium bromide staining of agarose gels (9). In our SNP typing studies, PCR primers were designed to produce amplification fragments up to 500 bp. Successful PCR amplifications using DOP-PCR products as template indicate that fragments of more than 500 bp in length can be obtained by DOP-PCR.

### 3.1.5. Amplification bias

Occasionally, we observe biased amplification of some heterozygous samples in mass SNP typing (see Fig. 4a, samples situated between clusters AA and CA, denoted by crosses). In this case, the amount of genomic DNA for some of the samples may not have been sufficient (see section 3.1.2). In addition, in microsatellite analysis, Grant *et al.* (10) noticed some preferential amplification of shorter alleles, although other reports have described equal amplification for microsatellites (9). It is important to take these points into consideration when using DOP-PCR-amplified DNA.



**Figure 4. SNP typing results using DOP-PCR and MDA products as template as determined by FCS (using roughly measured concentrations of genomic DNA).**

SNP IMS-JST115374 was analyzed in 246 samples. The genomic DNA concentration was roughly measured using a spectrophotometer. (a) Ten nanograms of genomic DNA was used as template for a 100  $\mu$ l DOP-PCR. One microlitre of fivefold-diluted product was used as template for the subsequent PCR. (b) Ten nanograms of genomic DNA was used as template for a 20  $\mu$ l MDA reaction (using the GenomiPhi Kit, Amersham Biosciences, according to the manufacturer's instructions). One microlitre of the 25-fold-diluted product was used as the template for the subsequent PCR. Samples are denoted by the corresponding genotype symbols as follows: ◇, CC; □, CA; △, AA; ○ and ×, not possible to judge. The x-axis shows the percentage of amplified product for 543 nm (TAMRA), while the y-axis shows the percentage of amplified product for 633 nm (Cy5).

### 3.1.6. Multiple-displacement amplification (MDA) provides greater accuracy in downstream genotyping assays

Recently, commercial kits (GenomiPhi, Amersham Biosciences; REPLI-g, Qiagen) employing MDA (see *Chapters 8–11*) have been used for WGA. When the amount of genomic DNA is sufficient (10 ng) for all samples, SNP typing using DOP-PCR products as template provides accurate results (see *Fig. 2*), comparable to those obtained using MDA products (see *Fig. 3*). However, we occasionally observed cases where MDA-generated DNA gave greater genotyping accuracy in mass SNP typing than DOP-PCR-generated DNA (see *Fig. 4*). In such cases, it is possible that suboptimal amounts of DNA are present in the DOP-PCR-amplified sample. When we compared DOP-PCR and MDA-amplified DNA for SNP typing, we succeeded in typing 82.1% (348 of 424) and 95.8% (68 out of 71) of the SNPs, respectively, when using the same genomic DNA template for WGA. For example, in *Fig. 4*, 34 out of 36 samples situated between clusters AA and CA (indicated by crosses) by DOP-PCR (see *Fig. 4a*) were classified in the CA cluster by MDA (see *Fig. 4b*).

## 3.2. Conclusion

SNP typing can be successfully performed using DOP-PCR-amplified DNA. However, it is important to ensure that sufficient starting template is used in the DOP-PCR and that an appropriate amount of DOP-PCR product is used for any subsequent PCRs. The genotypes determined by SSP-PCR and FCS using DOP-PCR samples were 100% in agreement with those determined by direct sequencing of genomic samples. Under these conditions, for most if not all cases, there should be no or very little biased amplification by DOP-PCR.

## 4. REFERENCES

- ★ ★ ★ 1. Telenius H, Carter NP, Bebb CE, Nordenskjöld M, Ponder BA & Tunnacliffe A (1992) *Genomics*, **13**, 718–725. – *First report of DOP-PCR*.
2. Dietmaier W, Hartmann A, Wallinger S, *et al.* (1999) *Am. J. Pathol.* **154**, 83–95.
3. Hirose Y, Aldape K, Takahashi M, Berger MS & Feuerstein BG (2001) *J. Mol. Diagn.* **3**, 62–67.
4. Huang Q, Schantz SP, Rao PH, Mo J, McCormick SA & Chaganti RS (2000) *Genes Chromosomes Cancer*, **28**, 395–403.
5. Kittler R, Stoneking M & Kayser M (2002) *Anal. Biochem.* **300**, 237–244.
6. Telenius H, Pelmeur AH, Tunnacliffe A, *et al.* (1992) *Genes Chromosomes Cancer*, **4**, 257–263.
7. Umayahara K, Numa F, Suehiro Y, *et al.* (2002) *Genes Chromosomes Cancer*, **33**, 98–102.
8. Kallioniemi A, Kallioniemi OP, Sudar D, *et al.* (1992) *Science*, **258**, 818–821.
- ★ 9. Cheung VG & Nelson SF (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 14676–14679. – *The use of DOP-PCR-amplified DNA in SNP genotyping*.
10. Grant SF, Steinlicht S, Nentwich U, Kern R, Burwinkel B & Tolle R (2002) *Nucleic Acids Res.* **30**, e125.
11. Bannai M, Higuchi K, Akasaka T, *et al.* (2004) *Anal. Biochem.* **327**, 215–221.
12. Jordan B, Charest A, Dowd JF, *et al.* (2002) *Proc. Natl. Acad. Sci. U. S. A.* **99**, 2942–2947.



## DigiTag assay for multiplex single nucleotide polymorphism typing with high success rate

Nao Nishida<sup>a,b,\*</sup>, Tetsuya Tanabe<sup>c</sup>, Kento Hashido<sup>b</sup>, Kouyuki Hirayasu<sup>a</sup>, Miwa Takasu<sup>a</sup>, Akira Suyama<sup>d</sup>, Katsushi Tokunaga<sup>a</sup>

<sup>a</sup> Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

<sup>b</sup> Biomedical Business Incubation Division, Olympus Corp., 2-3 Kuboyama-cho, Hachioji, Tokyo 192-8512, Japan

<sup>c</sup> R&D Division, NovusGene Inc., 2-3 Kuboyama-cho, Hachioji, Tokyo 192-8512, Japan

<sup>d</sup> Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan

Received 29 June 2005

Available online 31 August 2005

### Abstract

As a consequence of Human Genome Project and single nucleotide polymorphism (SNP) discovery projects, several millions of SNPs, which include possible susceptibility SNPs for multifactorial diseases, have been revealed. Accordingly, there has been a strong drive to perform the investigation with all candidate SNPs for a certain disease without decreasing the number of analyzed SNPs. We developed DigiTag assay, which uses well-designed oligonucleotides called DNA coded numbers (DCNs) in multiplex SNP genotype analysis. During the analysis, the information of a genotype is converted to one of the DCNs in a one to one manner using oligonucleotide ligation assay (encoding). After the encoding reaction, only the DCNs regions and not the SNP specific regions are amplified using the universal primers and then SNP genotype is read out using DNA capillary arrays. DigiTag assay was found to be successful in SNP genotyping, giving a high success rate (24 of 27 SNPs) for randomly chosen SNPs. Moreover, this assay has the potential to analyze almost all kinds of the target SNPs by applying mismatch-induced probes and redesigned primer pairs at a low-cost.

© 2005 Elsevier Inc. All rights reserved.

**Keywords:** Genotyping method; Multiplex genotyping; SNPs; Mutation; Oligonucleotide ligation assay

Numerous single nucleotide polymorphisms (SNPs)<sup>1</sup> are considered to be candidate susceptibility or resistance genetic factors for multifactorial diseases such as hypertension, diabetes, and rheumatic diseases [1–5]. Large-scale case–control analyses of SNPs in candidate genes have revealed associations between various diseases and SNPs with the highest detection power [6–8]. Moreover, genome-wide association studies using SNPs have become important in the search for susceptibility and/or resistance genes [9,10]. Accordingly, large-scale whole-genome genotyping projects need high-throughput, cost-effective, and highly

reliable technology to identify primary genes or SNPs. At present, there are a variety of SNP genotyping applications including microarray technology [11], molecular inversion probe genotyping [12], BeadArray genotyping technology (Illumina), 5' exonuclease fluorescence-based assay (TaqMan) [13], pyrosequencing [14], single-base extension [15], matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [16,17], and SNPlex (Applied Biosystems). However, many applications need to select relevant SNPs for their assay by *in silico* assay design, and then a portion of candidate SNPs will be excluded from investigation. To accomplish successful typing for all candidate SNPs at a low-cost, new technologies must be developed. In this study, we developed a new multiplex SNP typing method, named DigiTag assay, and performed typing for 28 SNPs using 40 genomic DNA samples. This approach

\* Corresponding author. Fax: +81 3 5802 8619.

E-mail address: [nishida-75@umin.ac.jp](mailto:nishida-75@umin.ac.jp) (N. Nishida).

<sup>1</sup> Abbreviations used: SNPs, single nucleotide polymorphisms; DCNs, DNA coded numbers; DTT, dithiothreitol; SSC, standard saline citrate.

uses well-designed oligonucleotides called DNA coded numbers (DCNs), which enable performance of multiplex SNP genotyping with high accuracy and reproducibility.

## Materials and methods

### DNA samples

Genomic DNA samples from 40 unrelated healthy donors were obtained from the Japan Health Science Foundation (Osaka, Japan). All donors provided written informed consent and samples were anonymized. One hundred nanograms of purified genomic DNA was dissolved in 20  $\mu$ l TE buffer, pH 8.0 (Wako, Osaka, Japan), for use and stored at 4 °C.

### Preparation of DNA coded numbers

DCNs were designed to be 69-mer oligonucleotides (Fig. 1). DCNs consist of three parts, designated SD (start-digit), D1 (first-digit), and ED (end-digit). SD and ED are the common DNA sequences prepared at both edges in all DCNs and are used for priming sites in the labeling step. D1s are different DNA sequences among DCNs and are used to identify SNPs of interest. We prepared two EDs (ED-1 and ED-2) for two alleles at each SNP. The sequences of the three DCN components have the same length of 23-mer and the uniform melting temperature of  $60.5 \pm 0.9$  °C. The assignment of DCNs to the SNPs analyzed in this study is listed in the Supplementary Table.

We designed DCNs (i) to have a uniform melting temperature and length, (ii) to ensure specific hybridization only to complementary DCNs, (iii) to minimize interaction with other DCNs, and (iv) to prevent the formation of secondary structures [18,19]. Therefore, all DCNs can be uniformly amplified in a multiplex manner using the common priming sites (SD, ED-1, and ED-2). Furthermore, we can perform precise hybridization on the DNA capillary array using a set of DCNs with high reproducibility.

### Multiplex PCR from sample DNA

We designed multiplex PCR primers for each of the 28 SNP sites to have relatively long-length (average length 40-mer) and to give PCR product lengths of between 200 and 800 bp (average PCR product length 464 bp). To avoid spurious amplification products, we performed multiplex PCR by a two-step protocol (denature and extension steps) with elongated extension step for 6 min using specifically designed primer pairs.

Multiplex PCR was performed with 2.5  $\mu$ l of genomic DNA and 1.25 pmol of primer pairs for 28 SNP sites in 50  $\mu$ l of Multiplex PCR buffer, 0.2  $\mu$ M dNTPs, and Hot-StarTaq DNA polymerase (Qiagen Multiplex PCR Kit, Qiagen, CA, USA). Cycling was performed as follows: 95 °C for 15 min, followed by 40 cycles of 95 °C for 30 s and




Fig. 1. Schematic representation of DigiTag assay. This assay has four steps to accomplish SNP typing: target preparation, encoding, labeling, and detection. DCNs are composed of three parts: SD, D1, and ED. SD and ED are the common DNA sequences prepared at both edges in all DCNs and are used for priming sites in the labeling step. Two EDs (ED-1 and ED-2) are prepared for two alleles at each SNP. D1s are different DNA sequences among DCNs and are used to identify SNPs of interest. DCN<sub>i</sub> includes the common priming sites (SD, ED-1, and ED-2) and variable sequence (D1<sub>i</sub>). Reverse complement sequences are written by attaching the character c before the sequence name.

68 °C for 6 min. When necessary, the fragment length of 28 PCR products was confirmed by capillary electrophoresis (Agilent 2100 Bioanalyzer, Agilent, CA, USA) to evaluate the PCR efficiency.

### Encoding reaction

We prepared two 5'-query probes and one 3'-query probe for a single SNP site (Fig. 1). The 5'-query probes have the sequence complementary to that of the 5' flanking of the target SNP (average length 20-mer) and each of the probes has an allele-specific sequence. Two types of DCNs, which have ED-1 and ED-2, were attached to each of the 5'-query probes. The 3'-query probe has the sequence complementary to that of the 3' flanking of the target SNP (average length 20-mer) and has a phosphate group on its 5' end and a biotin molecule on its 3' end.

Two microliters of multiplex PCR product was mixed in 30  $\mu$ l of 20 mM Tris–HCl, pH 7.6, 25 mM potassium acetate, 10 mM magnesium acetate, 10 mM DTT, 1 mM NAD, 0.1% Triton X-100 (*Taq* DNA ligase buffer, New England BioLabs, MA, USA) with 10 fmol of each probe (56 5'-query and 28 3'-query probes), 0.1  $\mu$ l of control mix, and 20 U *Taq* DNA ligase. The control mix was prepared to assess each step of this assay including (i) 10 fmol of control target oligonucleotides and 10 fmol of two 5'-query probes and one 3'-query probe (assigned to DCN\_29) for positive control of entire step, (ii) 0.1 fmol of 3' end biotinylated DCN\_30 for positive control of washing step with streptavidin-coupled magnetic beads, and (iii) 10 fmol of nonlabeled DCN\_31 for negative control of washing step with streptavidin-coupled magnetic beads. All components of the encoding reaction were mixed on ice. The encoding reaction was first held at 95 °C for 5 min, followed by 58 °C for 15 min. The reaction was stopped by holding temperature at 10 °C.

#### Labeling of DCNs

The ligated products were washed with 1  $\times$  binding and washing buffer (1 M NaCl, TE, pH 8.0) twice at room temperature after binding to streptavidin-coupled magnetic beads (Dynabeads M-280 streptavidin, Dynal, Oslo, Norway), following the manufacturer's protocol. Alkali denaturation was performed to remove the multiplex PCR product and then asymmetric PCR was performed with single-strands of the ligated products binding to streptavidin-coupled magnetic beads, 1.0 pmol of SD, 10.0 pmol of Cy3-labeled reverse complement of ED-1 (Cy3-cED-1), 10.0 pmol of Cy5-labeled reverse complement of ED-2 (Cy5-cED-2), 2.5 U of *Ex Taq* polymerase in a 20  $\mu$ l of 20 mM Tris–HCl, pH 8.0, 100 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5% Tween 20, 0.5% Nonidet P-40, 50% glycerol, 2 mM each dNTP (*Ex Taq* Buffer, TaKaRa, Shiga, Japan). Asymmetric PCR was first held at 95 °C for 1 min, followed by 20 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s.

#### Hybridization and detection on DNA capillary array

The DNA capillary array is a DNA detection device integrating oligonucleotide probes attached to specific locations in eight-parallel capillaries on a slide glass (see Fig. 3B, Olympus, Tokyo, Japan). Thirty-two types of oligonucleotide probes (28 probes for 28 SNPs and 4 probes for validation controls of the assay) identical to D1 sequences of DCNs were immobilized in each capillary. The ready-to-use DNA capillary arrays were stored in a desiccator at room temperature until use.

A hybridization mixture was prepared by mixing the supernatant of asymmetric PCR mixture in 24  $\mu$ l of hybridization buffer containing 0.5  $\times$  SSC, 0.1% SDS, 15% formamide, 1 mM EDTA, with 2  $\mu$ l of hybridization control. The hybridization control for ensuring the hybridization step

was prepared with 5 fmol of Cy3-labeled D1\_32 and Cy5-labeled D1\_32. Twenty microliters of the hybridization mixture was applied to each capillary on the DNA capillary array. Hybridization was carried out for 30 min at 37 °C in a hybridization oven. After hybridization, the glass slides were washed in a washing buffer (0.1  $\times$  SSC, 0.1% SDS) by shaking at 60 rpm for 5 min. The glass slides were consecutively washed in distilled water by shaking at 60 rpm for 1 min and then dried by centrifugation at 2000 rpm for 1 min. Hybridization images were scanned at photomultiplier voltages of 400 V for Cy3 and 520 V for Cy5 using a commercially available DNA chip scanner and fluorescence image analysis was performed using commercially available software (GenePix 4000B unit and GenePix Pro 4.1 software package, Axon Instruments, CA, USA).

## Results

### Schematic representation of DigiTag assay

This assay is performed in four steps: target preparation, encoding, labeling, and detection (Fig. 1). In this assay, multiplex PCR is performed with genomic DNA to prepare target fragments before the encoding step. For multiplex PCR, we designed the primer pairs to have 40-mer in average length and performed multiplex PCR by a two-step protocol (denature and extension steps) with elongated extension step for 6 min. The long-length primers and elongated extension step are essential for multiplex PCR to uniformly amplify all of the target fragments. In the encoding step, the 5'-query probe and 3'-query probe are successfully concatenated by *Taq* DNA ligase when two probes are fully complementary to adjacent regions on the target fragment [20]. The information of genotype is converted to one of the DCNs by a one to one manner in the encoding step. After the encoding step, single-strand forms of alkali denatured ligation products serve as templates in asymmetric PCR using Cy3- and Cy5-labeled primer pairs (SD, Cy3-cED-1, and Cy5-cED-2). The Cy3- and Cy5-labeled PCR products are gathered as single-strand forms of complementary DCNs and are then hybridized with the D1 probes on the DNA capillary array to reveal SNP genotypes by reading the signals from the various D1s. If the genomic DNA sample is homozygous for a certain SNP, a single color signal from Cy3 or Cy5 is detected from the corresponding spot on the DNA capillary array. In contrast, both signals are present when the sample is heterozygous.

### Optimization of reaction condition in encoding step and DCN amplification rate

We first investigated the ligation conditions in the encoding step using a SNP located in the *PLOD* gene on human chromosome 1p36 as a model SNP (JSNP ID IMS-JST068774). We prepared four types of 5'-query probes with four types of DCNs, each of which had one of the original SNP bases G and C and the two artificial SNP bases A




Fig. 2. Encoding rates of four SNP bases at different ligation temperatures. Encoding rate was compared as the amount of PCR product in the combination with four types of 5'-query probes and four types of target oligonucleotides. NC means that no target was included in the encoding reaction. Average amount of PCR product was calculated from three independent experiments. (A) The ligation reaction was performed at three temperatures: 55, 60, and 65 °C for 15 min. (B) The ligation reaction was performed at 58 °C for 15 min.

and T (see Supplementary Table). To investigate the encoding conditions, we prepared four types of 30-base target oligonucleotides identical to the SNP specific sequences. The encoding conditions were investigated by varying the ligation temperature from 55 to 65 °C (Fig. 2A). The encoding rate was compared as the amount of PCR products after performing 25 cycles of PCR with SD and reverse complement of ED (cED) primers using the ligated products as templates. When the ligation reaction was performed at 58 °C for 15 min, the signal intensities from perfect-match pair of 5'-query probe and target oligonucleotide were substantially higher than those from non-perfect-match pairs (Fig. 2B). False-positive signals were also suppressed at this ligation condition among the four SNP bases. False-positive signals increased at lower ligation temperatures, particularly when G-T mismatch occurred between 5'-query probe and target oligonucleotide. The intensities of positive signals decreased with ligation temperatures above 58 °C. Moreover, it became clear that the SNP base should be located at the 3' end of the 5'-query probes to ensure precise discrimination between alleles (data not shown). When the SNP base was located at the 5' end of the 3'-query probe, false-positive signals were significantly high and therefore resulted in incorrect genotyping.

PCR amplification rate was investigated by real-time PCR among DCNs used in multiplex SNP typing. A single DCN was added to a separate tube in 10-fold dilutions between 100 and 1 pM. PCR amplification rates of each DCN were calculated based on the results of real-time PCR. As expected, PCR amplification rate was found to be uniform at about 1.8 at concentrations between 100 and 1 pM (data not shown).

#### Multiplex typing for 28 SNPs using 40 genomic DNA samples

We then randomly selected 28 SNPs from a 500-kb region including the *IL-4* and *IL-13* genes on human chro-

mosome 5q31-33, which contains several candidate genes related to immune disorders. We subsequently designed probes for the 28 SNP sites to give properties similar to those for *PLOD* SNP to obtain similar ligation efficiency among the 28 SNP sites to be analyzed in a single tube. The 5'-query probes and 3'-query probes were designed to have the uniform melting temperatures,  $52.9 \pm 1.8$  and  $55.0 \pm 1.4$  °C, respectively. The SNP genotypes of 40 genomic DNA samples were alternatively determined by direct sequencing and were used as reference data.

Multiplex PCR products including the 28 SNP sites showed similar band patterns with different individual DNA samples, although it was difficult to clearly discern all 28 PCR products due to the limitation of the electrophoretic resolution (Fig. 3A). Multiplex SNP typing for 28 SNPs was then performed using the multiplex PCR products as targets. The DNA capillary array demonstrated hybridization images of each sample in each capillary having 32 spots (28 probes for 28 SNPs and 4 probes for validation controls, see Fig. 3B). The hybridization image was analyzed using a DNA chip scanner, and the Cy3 and Cy5 signal intensities of each spot were plotted to produce a scatter diagram (Fig. 3C). The SNP 13 was monomorphic in 40 genomic DNA samples and was excluded from further analysis. For 24 SNPs (except for SNP 6, SNP 9, and SNP 19), three distinct clusters corresponding to two homozygous and one heterozygous genotypes were observed, although the average signal intensity for the 24 SNP sites fluctuated between 100 and 16,000. The fluctuated intensities presumably result from different efficiencies of PCR in the target preparation step by the multiplex PCR.

Indistinct clusters were observed for SNP 6, SNP 9, and SNP 19. For SNP 6 and SNP 9, the false-positive signals were detected when we performed singleplex SNP typing using target oligonucleotides identical to the SNP specific sequences (Figs. 4A and B). To suppress the false-positive signals observed from SNP 6 and SNP 9, we prepared






Fig. 3. Multiplex SNP typing for 28 SNPs using 40 genomic DNA samples. (A) Gel images of multiplex PCR products with different individual samples. In all sample lanes, the sample bands were observed between two inner markers; 15 and 1500 bp. (B) Hybridization images of the DNA capillary array. (C) Scatter diagrams for randomly chosen 6 SNPs from 28 SNPs.

three types of mismatch-induced 5'-query probes, which had an artificial mismatch at the fourth position from the SNP base. The encoding rate was investigated using mismatch-induced 5'-query probes and target oligonucleotides identical to the SNP specific sequences by comparing the amount of PCR products after performing 25 cycles of PCR using the ligated products as templates. All of the three mismatch-induced 5'-query probes can effectively suppress the false-positive signals without diminishing the positive signals from the perfect-match pair of the mismatch-induced 5'-query probe and target oligonucleotide (Figs. 4A and B). We then performed multiplex typing

using one of the mismatch-induced 5'-query probes for each of two SNPs. Scatter diagrams showed that three clusters from perfect-match 5'-query probes were indistinctly observed (Figs. 4C and D) as compared to the mismatch-induced 5'-query probes (Figs. 4E and F). For SNP 19, many samples did not belong to any clusters, presumably due to insufficient amplification of the target fragment in multiplex PCR.

In 24 successfully genotyped 24 SNPs, 8 miscallings were observed among 960 genotypes. The percentage of calling rate (number of identified SNPs divided by the total number examined) was 99.2% and the concordance rate with




Fig. 4. Suppression of false-positive signals by mismatch-induced 5'-query probes. (A and B) Both graphs show the singleplex typing result of SNP 6 and SNP 9, respectively. PM indicates the perfect-match pair of 5'-query probe and target oligonucleotide. Three types of mismatch-induced 5'-query probes which had an artificial mismatch base at the fourth position from the SNP base were prepared (mmA, mmG, and mmC for SNP 6; mmA, mmT, and mmC for SNP 9). P and FP mean positive signals and false-positive signals, respectively. Scatter diagrams show the multiplex typing result of SNP 6 and SNP 9, respectively: (C and D) using perfect-match 5'-query probes and (E and F) using mismatch-induced 5'-query probes (mmC for SNP 6, mmA for SNP 9).

reference data from direct sequencing was 100%. The reproducibility of this assay was examined by duplicate experiments and was observed higher than 0.99 in  $r^2$  except for 2 SNPs (SNP 2, 0.96; SNP 20, 0.96).

## Discussion

We developed DigiTag assay and performed multiplex typing for 28 SNPs using 40 genomic DNA samples. One of the 28 SNPs (SNP 13) was revealed to be monomorphic in 40 samples and was therefore excluded from further analysis. This assay was found to be successful in SNP genotyping, giving a high success rate (24 of 27 SNPs) for randomly chosen SNPs. Three SNPs of 27 SNPs showed indistinct clusters, presumably resulting from missligation in the encoding step (SNP 6 and SNP 9) and insufficient amplification in the multiplex PCR (SNP 19).

The missligation was reported to be prone to occur when mismatched pairs are G-T, G-A, G-G, and A-G [21]. In our results, one of two missligated SNPs had G-G mismatch (SNP 6) and another one had G-T mismatch (SNP 9) between the 5'-query probe and the target fragment. The missligation results in increasing the false-positive signals and then leads to ambiguous genotyping. To suppress the false-positive signals, we designed mismatch-induced 5'-query probes, which had an artificial mismatched base at the fourth position from the SNP base. The mismatch-induced 5'-query probes could effectively suppress the false-positive signals without diminishing the positive signals.

Multiplex PCR has the potential to reduce the complexity fraction of the genome by selectively collecting the target SNP sites from the genome, which would lead to successful genotyping [22]. However, it was also reported that the presence of multiple primer pairs increases the chance of obtain-

ing spurious amplification products such as primer dimers [23]. To avoid spurious amplification products, we designed primer pairs to have relatively long-length (average length 40-mer) and performed multiplex PCR by a two-step protocol with an elongated extension step for 6 min. This optimization of multiplex PCR leads to all of the target fragments being obtained. In contrast, insufficient amplification was observed for SNP 19 in this assay, such target fragment would be reamplified using a different primer pair.

The newly developed DigiTag assay described in this paper has the potential to accurately analyze almost all kinds of SNPs by applying mismatch-induced 5'-query probes and redesigned primer pairs. In this assay, the genotype information is encoded to one of the well-designed oligonucleotides called DCNs, which enable performance of SNP genotyping with high accuracy and reproducibility. Moreover, this assay has several other advantages: (i) any set of SNPs can be analyzed by the same DNA capillary array having the same set of probes, because the same set of DCNs can be unrestrainedly assigned to any set of target SNPs, thus reducing the cost of genotyping; (ii) oligonucleotide ligation assay, used in the encoding step, enables one to execute multiplex SNP typing; (iii) the same set of DCNs can also be used for other applications, such as gene expression profiling, thus ensuring low-cost analysis of genomic information [19,24]; and (iv) this assay can be readily adapted to high-throughput typing using automated equipment or a robot.

We have already prepared more than 100 available DCNs to perform SNP genotyping. We are currently attempting to scale up this technique to perform multiplex SNP typing for 100–500 SNPs using an improved DNA capillary array with more capillaries and probes. Our preliminary results show that this assay could perform multiplex typing for more than 100 SNPs if the target fragments are sufficiently amplified in the multiplex PCR. It would be essential to find an upper limit on the multiplex PCR, which forms a bottleneck for multiplexing. The simplification and automation of the assay protocols would lead to execution of multiplex genotyping in a high-throughput form.

#### Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research on Priority Areas (C) and by the New Energy and Industrial Technology Development Organization.

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ab.2005.08.007.

#### References

- [1] X. Zhu, Y.-P.C. Chang, D. Yan, A. Weder, R. Cooper, A. Luke, D. Kan, A. Chakravarti, Associations between hypertension and genes in the renin-angiotensin system, *Hypertension* 41 (2003) 1027–1034.

- [2] T. Nakajima, L.B. Jorde, T. Ishigami, S. Umemura, M. Emi, J.-M. Lalouel, I. Inoue, Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations, *Am. J. Hum. Genet.* 70 (2002) 108–123.
- [3] Y. Horikawa, N. Oda, N.J. Cox, X. Li, M. Orho-Melander, M. Hara, Y. Hinokio, T.H. Lindner, H. Mashima, P.E.H. Schwarz, L. del Bosque-Plata, Y. Horikawa, Y. Oda, I. Yoshiuchi, S. Colilla, K.S. Polonsky, S. Wei, P. Concannon, N. Iwasaki, J. Schulze, L.J. Baier, C. Bogardus, L. Groop, E. Boerwinkle, C.L. Hanis, G.I. Bell, Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus, *Nat. Genet.* 26 (2000) 163–175.
- [4] D. Altshuler, J.N. Hirschhorn, M. Klannemark, C.M. Lindgren, M.-C. Vohl, J. Nemesh, C.R. Lane, S.F. Schaffner, S. Bolk, C. Brewer, T. Tuomi, D. Gaudet, T.J. Hudson, M. Daly, L. Groop, E.S. Lander, The common PPAR $\gamma$  Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes, *Nat. Genet.* 26 (2000) 76–80.
- [5] A. Suzuki, R. Yamada, X. Chang, S. Tokuhira, T. Sawada, M. Suzuki, M. Nagasaki, M. Nakayama-Hamada, R. Kawaida, M. Ono, M. Ohtsuki, H. Furukawa, S. Yoshino, M. Yukioka, S. Tohma, T. Matsubara, S. Wakitani, R. Teshima, Y. Nishioka, A. Sekine, A. Iida, A. Takahashi, T. Tsunoda, Y. Nakamura, K. Yamamoto, Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis, *Nat. Genet.* 34 (2003) 395–402.
- [6] N. Tsuchiya, J. Ohashi, K. Tokunaga, Variations in immune response genes and their associations with multifactorial immune disorders, *Immunol. Rev.* 190 (2002) 169–181.
- [7] J. Ohashi, K. Tokunaga, The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers, *J. Hum. Genet.* 46 (2001) 478–482.
- [8] A. Wille, J. Hoh, J. Ott, Sum statistics for the joint detection of multiple disease loci in case-control association studies with SNP markers, *Genet. Epidemiol.* 25 (2003) 350–359.
- [9] C.S. Carlson, M.A. Eberle, L. Kruglyak, D.A. Nickerson, Mapping complex disease loci in whole-genome association studies, *Nature* 429 (2004) 446–452.
- [10] R. Yamada, S. Tokuhira, X. Chang, K. Yamamoto, SLC22A4 and RUNX1: identification of RA susceptible genes, *J. Mol. Med.* 82 (2004) 558–564.
- [11] D.G. Wang, J.-B. Fan, C.-J. Siao, A. Berno, P. Young, R. Sapolsky, G. Ghandour, N. Perkins, E. Winchester, J. Spencer, L. Kruglyak, L. Stein, L. Hsie, T. Topaloglou, E. Hubbell, E. Robinson, M. Mittmann, M.S. Morris, N. Shen, D. Kilburn, J. Rioux, C. Nusbaum, S. Rozen, T.J. Hudson, R. Lipshutz, M. Chee, E.S. Lander, Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome, *Science* 280 (1998) 1077–1082.
- [12] P. Hardenbol, J. Banér, M. Jain, M. Nilsson, E.A. Namsaraev, G.A. Karlin-Neumann, H. Fakhrai-Rad, M. Ronaghi, T.D. Willis, U. Landegren, R.W. Davis, Multiplexed genotyping with sequence-tagged molecular inversion probes, *Nat. Biotechnol.* 21 (2003) 673–678.
- [13] P.M. Holland, R.D. Abramson, R. Watson, D.H. Gelfand, Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of *Thermus aquaticus* DNA polymerase, *Proc. Natl. Acad. Sci. USA* 88 (1991) 7276–7280.
- [14] N. Pourmand, E. Elahi, R.W. Davis, M. Ronaghi, Multiplex pyrosequencing, *Nucleic Acids Res.* 30 (2002) e31.
- [15] K. Lindroos, U. Liljedahl, M. Raitio, A.-C. Syvänen, Minisequencing on oligonucleotide microarrays: comparison of immobilisation chemistries, *Nucleic Acids Res.* 29 (2001) e69.
- [16] J. Tost, I.G. Gut, Genotyping single nucleotide polymorphisms by mass spectrometry, *Mass Spectrom. Rev.* 21 (2002) 388–418.
- [17] M.S. Bray, E. Boerwinkle, P.A. Doris, High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise, *Hum. Mutat.* 17 (2001) 296–304.
- [18] H. Yoshida, A. Suyama, Solution to 3-SAT by breadth first search, DIMACS Series in Discrete Mathematics and Theoretical Computer Science 54 (2000) 9–22.

- [19] N. Nishida, M. Wakui, K. Tokunaga, A. Suyama, Highly specific and quantitative gene expression profiling based on DNA computing, *Genome Inform.* 12 (2001) 259–260.
- [20] F. Barany, Genetic disease detection and DNA amplification using cloned thermostable ligase, *Proc. Natl. Acad. Sci. USA* 88 (1991) 189–193.
- [21] J.N. Housby, E.M. Southern, Fidelity of DNA ligation: a novel experimental approach based on the polymerisation of libraries of oligonucleotides, *Nucleic Acids Res.* 26 (1998) 4259–4266.
- [22] H. Matsuzaki, H. Loi, S. Dong, Y.-Y. Tsai, J. Fang, J. Law, X. Di, W.-M. Liu, G. Yang, G. Liu, J. Huang, G.C. Kennedy, T.B. Ryder, G.A. Marcus, P.S. Walsh, M.D. Shriver, J.M. Puck, K.W. Jones, R. Mei, Parallel Genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array, *Genome Res.* 14 (2004) 414–425.
- [23] P. Markoulatos, N. Siafakas, M. Moncany, Multiplex polymerase chain reaction: a practical approach, *J. Clin. Lab. Anal.* 16 (2002) 47–51.
- [24] Y. Sakakibara, A. Suyama, Intelligent DNA chips: Logical operation of gene expression profiles on DNA computers, *Genome Inform.* 11 (2000) 33–42.